==> picture [343 x 60] intentionally omitted <==

Investor Presentation Financial Year 2020 2[nd] June 2020

==> picture [198 x 78] intentionally omitted <==

Safe Harbor

Certain statements in this presentation concerning our future growth prospects are forward looking statements, which involve a number of risks, and uncertainties that could cause actual results to differ materially from those in such forward looking statements. The company's results may be affected by factors including, but not limited to, the risks and uncertainties in pharmaceutical research and development; competitive developments; regulatory actions; the extent and duration of the effects of the COVID-19 pandemic; litigation and investigations; business development transactions; economic conditions; and changes in laws and regulations, including health care reform. The company undertakes no duty to update forward-looking statements except as required by applicable law.

FY20 Highlights

==> picture [394 x 395] intentionally omitted <==

----- Start of picture text -----

12.9% 40.8%
(YoY) (YoY)
Revenue EBITDA
PAT Cash
50.1% 93.7
(YoY) ₹ crore
As on ‘Mar-20
----- End of picture text -----

==> picture [216 x 147] intentionally omitted <==

Mark Saldanha Managing Director And CEO

“I am extremely delighted to share with you the strong performance in this fiscal despite the lockdown due to the COVID pandemic at the end of March. Revenue for the year expanded by ~13% and EBITDA by ~41%. We also received EIR from the US FDA for Time Cap Laboratories located at Farmingdale, New York, USA . This positions us favorably to expand our reach in US market.

On the financial front we became a zero-debt with company cash of Rs 94 crore at the end of this fiscal. The outlook for FY21 looks positive and we expect the growth momentum to continue.”

Operational Excellence leading to positive margin & return ratios

==> picture [880 x 390] intentionally omitted <==

----- Start of picture text -----

EBITDA & PAT Margin ROCE
16.97% 24.50%
EBITDA Margin
13.61% 19.96%
PAT Margin 10.64%
9.51%
8.01% 12.06%
6.69%
3.90% 4.76%
1.46%
Mar-17 Mar-18 Mar-19 Mar-20 Mar-17 Mar-18 Mar-19 Mar-20
Net Debt to EBITDA (x) ROE 18.60%
1.63
14.55%
0.89
0.49 7.45%
-0.39
2.58%
Mar-17 Mar-18 Mar-19 Mar-20 Mar-17 Mar-18 Mar-19 Mar-20
----- End of picture text -----

Ratios calculated using standardized financial formula

==> picture [247 x 45] intentionally omitted <==

Agenda

§ Q4 & FY20 Performance Review
§ Operational review and financials
§ Company at a glance
§ Long-term strategy
§ Research & development
§ Segmental revenue composition
§ Investment rationale

==> picture [960 x 242] intentionally omitted <==

Q4 & FY20 Performance Review

Growth in Profitability

Rs. Cr.	FY20	FY19	YoY Growth (%)	YoY% (Constant currency)	Q4FY20	Q4FY19	YoY Growth (%)	YoY% (Constant currency)
Total Revenue	1,134.5	1,004.7	12.9%	15.8%	335.4	257.1	30.4%	33.9%
EBITDA	192.6	136.8	40.8%	41.1%	69.2	25.4	172.8%	173.4%
*EBITDA Margin%*	17.0%	13.6%	336 bps	297 bps	20.6%	9.9%	1,077 bps	1,028 bps
PAT	120.8	80.4	50.1%	50.5%	42.7	9.9	333.8%	334.8%
*PAT Margin%*	10.6%	8.0%	264 bps	239 bps	12.7%	3.8%	891 bps	861 bps

Key Highlights

Overall business grew by 12.9% in FY20 when compared to FY19
Growth was led by strong growth across key market of UK, US and Australia
EBITDA was Rs. 192.6 cr. as compared to Rs. 136.8 Cr. in FY19, an increase of 40.8%
PAT stood at Rs. 120.8 cr. as compared to Rs. 80.4 cr. in FY19, a growth of 50.1%

Source – Company Data

Financials

Consolidated (₹ Cr.)	Q4’20	Q3’20	Q4’19	FY'20	FY'19
Total Revenue	335.4	287.7	257.1	1,134.5	1,004.7
Material Consumption	147.8	140.1	122.8	544.9	498.0
Gross Profit	187.5	147.5	124.7	589.3	502.1
Gross Margin%	55.9%	51.3%	50.4%	52.0%	50.2%
OperatingExpenses	118.3	100.2	109.0	397.1	369.9
EBITDA	69.2	47.3	25.4	192.6	136.8
EBITDA Margin%	20.6%	16.4%	9.9%	17.0%	13.6%
Finance Cost	2.0	1.6	2.4	8.7	9.7
Depreciationand amortization	9.6	7.3	6.3	26.7	22.8
Earnings Before Tax	57.6	38.3	16.7	157.2	104.3
Taxes	14.8	8.8	6.8	36.4	23.9
Earnings After Tax	42.7	29.6	9.9	120.8	80.4
PAT Margin%	12.7%	10.3%	3.8%	10.6%	8.0%

*Gross Profit & Gross Margin is calculated using revenue from operation

Source – Company Data

Business Review

Rs. Cr.	FY20	FY19	YoY% (Constant currency)
Europe, UK	510.0	413.0 23.5%	27.6% 44.9%
US & North America	436.4	411.5 6.1%	6.3% 38.5%
Australia & NZ	140.7	119.9 17.3%	26.6% 12.4%
Rest of World (ROW)	47.4	60.3 -21.3%	-21.1% 4.2%
Consolidated Revenue from operations	1,134.5	1,004.7 12.9%	15.8% 100.0%

Key Highlights

Almost 96% of company's total revenue came from regulated markets of US, Europe, Australia and New Zealand

Formulation business from Europe, UK was Rs. 510.0 cr. this fiscal as compared to Rs. 413.0 cr. achieved during same period last year registering a growth of 23.5%
US & North America reported growth of 6.1% to Rs 436.4 cr. in FY20
Australia & NZ revenue was at Rs. 140.7 cr. in FY20, registering growth of 17.3% YoY

Source – Company Data

==> picture [960 x 242] intentionally omitted <==

Operational review and financials

Consolidated Revenue up 12.9% led by Strong Growth in Europe and Australia

==> picture [456 x 404] intentionally omitted <==

----- Start of picture text -----

Revenue (₹ Cr.)
13.6%
FY20 1,134.5
FY19 1,004.7
FY18 913.1
FY17 774.2
From FY17 to FY20
Revenue by market (₹ Cr.)
Europe, UK US & North America Australia & NZ RoW
1200.0
47.4
60.3
1000.0 140.7
35.4
119.9
33.0 99.1
800.0
436.4
105.6
600.0 371.5 411.5
349.4
400.0
510.0
200.0 415.2 413.0
286.2
0.0
FY17 FY18 FY19 FY20
CAGR
----- End of picture text -----

Topline driven by key geographies

The revenue growth in FY20 was driven by increasing market share in the US & North American region

US Region:

Revenue from the US market grew 6.06% over FY19, contributing to ~38% of the total revenues
Time Cap Labs Inc has achieved revenue of USD 59.23 Millions (FY 19-USD 57.91 Millions)

UK Europe:

Strong product pipeline followed by successful launches every quarter
In Europe, UK, company targets focused segments where competition is low
There is a consistency in the top line generation and will be followed by existing pipeline and future launches

Source – Company Data

EBITDA Margin Increased by 336 bps during FY20 – Strong Growth Expected in FY 21

==> picture [123 x 18] intentionally omitted <==

----- Start of picture text -----

EBITDA (₹ Cr.)
----- End of picture text -----

EBITDA Margin (%)

==> picture [431 x 358] intentionally omitted <==

----- Start of picture text -----

17.0%
FY20 192.6 54.9%
13.6%
FY19 136.8
9.5%
6.7%
FY18 86.9
FY17 51.8
From FY17 to FY17 FY18 FY19 FY20
FY20
PAT (₹ Cr.) PAT Margin (%)
10.6%
FY20 120.8 139.4%
8.0%
FY19 80.4
3.6%
FY18 32.9
1.1%
FY17 8.8
From FY17 to FY17 FY18 FY19 FY20
FY20
CAGR
CAGR
----- End of picture text -----

Steady growth in the profitability

Gross margin improved from 50.2% during FY19 to 52.0% in FY20 due to better product mix in US, UK and Europe
FY 20 had a 336 bps increase in EBITDA margin. This was the result of enriching product basket with superior products and higher improved operating efficiency across the business

PAT margins have improved from a low single digit to almost 10.6% in FY 20.

Source – Annual Report

Balance Sheet Trends (Mar 20 vs Mar 19)

Particulars (₹ Cr.). Mar-20 Mar-19	0.49 -0.39 Mar 19 Mar 20 Net Debt to EBITDA 19.96% 24.50% Mar 19 Mar 20 RoCE 14.55% 18.60% Mar 19 Mar 20 RoE • The Company’s cash balance as on March 2020 is ₹93.7 cr • Strong ROCE of 24.5% • Net debt to EBITDA as on March 2020 is -0.39 as company has zero net debt (including long-term and short-term borrowing) Highlights Ratios calculated using standardized financial formula	14.55% 18.60% Mar 19 Mar 20 RoE	19.96% 24.50% Mar 19 Mar 20 RoCE	0.49 -0.39 Mar 19 Mar 20 Net Debt to EBITDA
Net Worth 636.0 542.5
Capital Employed 677.2 571.1
Net debt -74.9 66.4
Cash & Bank Balance 93.7 33.5
Inventories 241.8 293.3
WC Cycle 119 days 109 days
Asset Turnover 1.33x 1.31x

Source – Company Data

==> picture [960 x 242] intentionally omitted <==

Company at a glance

Company Overview

Business Description

Business Model

Marksans Pharma Ltd., headquartered at Mumbai, is engaged in Research, Manufacturing & Marketing of generic pharmaceutical formulations
Key focus areas lie in OTC & prescription (Rx) drugs
Company manufactures tablets (plain, enteric coated and film coated), hard & soft gelatin capsule, oral liquids and ointments
Its manufacturing facilities are accredited by USFDA, UKMHRA and Australian TGA

==> picture [44 x 31] intentionally omitted <==

==> picture [37 x 37] intentionally omitted <==

96% of revenues comes from regulated markets
Forward-integrated business model
Presence in niche softgel segment

==> picture [879 x 210] intentionally omitted <==

----- Start of picture text -----

Revenue Mix Geographic Mix Product Portfolio Rs. Cr.
Rx Australia & RoW Pain Management 297
4.16%
OTC 45% NZ Cardiovascular System (CVS) 156
55% 12.34% Europe,
Cough & Cold 139
UK
44.71% Central Nervous System (CNS) 115
Anti-diabetic 107
FY20
FY20
Gastrointestinal 86
Miscellaneous 55
US & North
Anti-Allergic 29
America
Antibiotics 21
38.79%
(FY19)
----- End of picture text -----

Marksans Pharma Evolution

Investment Phase Consolidation Phase Recovery Phase Growth Phase FY05 - 09 FY10 - 12 FY13 - 16 FY17 - 20

Acquired 3 companies:
Nova Pharmaceuticals Australasia Pty. Ltd.
Bell, Sons & Co. (Druggists) Limited
Relonchem Limited
Increased ANDA filings and invested in site transfers (products of newly-acquired companies) to India
Integration of acquired companies was running slower than expected
Adverse forex movement during this phase post the global financial crisis
Acquired Time-Cap Laboratories Inc.
The Company crossed Rs 1000 crore in revenues for the first time in FY19
Strategized focus on specific verticals and identified nonperforming products
Emerged out as a forward integrated robust business model comprising R&D, inhouse manufacture and direct distribution
Reduced liabilities and repaid debts
Improved operating performance with Advil sales in the US ramping up and performances of subsidiary businesses stabilizing
Able to address sectoral opportunities and grow sustainably
Commissioned a new R&D center at Navi Mumbai, apart from one in Goa
Acquired 10 ANDA approvals and built a robust pipeline with 10 more ANDAs filed
Received EIR receipt from the US FDA for Time Cap Laboratories
Company became debt free

Business Model

==> picture [73 x 73] intentionally omitted <==

Focus on Regulated Forward integrated Markets business model

==> picture [74 x 73] intentionally omitted <==

Wider product basket

Marksans commenced business with CRAMS directed at the UK and Australian markets
Entered the regulated Australian market with the acquisition of Nova in 2005
Entered the regulated UK market with the acquisition of Bell Sons & Company Ltd. in 2007 and Relonchem Limited in 2008
Entered the US market in 201112 and acquired Time-Cap Laboratories in 2015
The Company now has a global presence across 25 countries
Marksans commenced operations as a formulations manufacturing enterprise
• The Company entered front-end marketing in regulated markets through acquisitions
Marksans commenced its journey with products addressing the pain management segment
The Company focused on highgrowth areas impacted by lifestyle disorders
•
The Company was among a few The Company launched soft Indian mid-sized companies with gelatin capsules, a niche frontend marketing capabilities category
• • The Company invested in a state The Company now offers of- the-art R&D facility, products across >10 therapeutic strengthening integration segments

Company Structure

==> picture [853 x 68] intentionally omitted <==

==> picture [889 x 236] intentionally omitted <==

----- Start of picture text -----

Marksans Pharma
(UK) Limited
Marksans
Holdings Limited
Distribution of quality
85+ product
generic pharma; only OTC;
licenses;
Wholesale Regional sales development
Manufacturer of distributor of Manufacturer of range of across Asia (China, Japan,
Singapore, Vietnam, Sri
OTC Liquids & generic pharma OTC & Rx products; 30+
Ointments products portfolio Lanka and South Korea)
----- End of picture text -----

Manufacturing Capabilities

Goa, India Southport, UK
• • Manufactures oral solid tablets and soft Manufactures non-sterile liquids, gelatin capsules ointments and powder products
• • One of the biggest manufacturing facility Supplies to UK, West Africa & Middle East in Asia having 18,000 square mtr campus
Farmingdale, USA
• Manufactures soft gels, tablets and capsules
• Spread across an area of 7000 sq. m
• "Made in the USA” product offering
Capacity
• 6 bn tablets and hard capsules per annum

Capacity

• •
2.4 bn softgel and hard gelatin capsules 13.6 mn bottles per annum per annum • 7.8 mn tubes per annum annum
• • 5 bn tablets per annum 5.7 mn sachets per annum
Accreditations Accreditations Accreditations

==> picture [88 x 55] intentionally omitted <==

==> picture [112 x 43] intentionally omitted <==

==> picture [146 x 91] intentionally omitted <==

==> picture [206 x 78] intentionally omitted <==

==> picture [68 x 65] intentionally omitted <==

==> picture [98 x 55] intentionally omitted <==

==> picture [960 x 242] intentionally omitted <==

Long-term strategy

Strategic focus on Regulated Markets

Marksans Pharma generates ~96% of its revenues from regulated markets

==> picture [129 x 132] intentionally omitted <==

==> picture [158 x 98] intentionally omitted <==

USA UK

==> picture [131 x 132] intentionally omitted <==

==> picture [144 x 144] intentionally omitted <==

New Zealand

Australia

Marksans Pharma entered strategic tie-ups and acquired key players in major markets to expand its global footprint
Company can generate higher margins by eliminating third parties from the value chain
Currently, the company markets products in 25+ countries with the UK and the US being the largest
Other prominent markets include Australia, New Zealand, Canada and several other European countries
These markets are empowered with regulatory approvals which allows the company to sell its products without restrictions
Marksans is among a handful of Indian players with a proprietary marketing presence in the world’s largest pharma market such as US, UK and Australia
The Company expects to expand in the regulated markets through integrated product development, cGMP compliance, regulatory compliance and utilization of latest technologies

Niche Formulations with few Competitors

Marksans Pharma is currently one of the most active Indian firms focused in Softgel segment

Differentiated offerings : Focused on softgel capsules with a view to build a differentiated set of offerings in the crowded generics market

==> picture [349 x 218] intentionally omitted <==

Limited competition - Given the challenges in preparing Softgel formulations plus other economic, technical and patent constraints there are not many players in this segment
High barriers to entry – High capex requirements and operational costs further restrict entry
Selectively targeted larger markets : Marksans has filed softgel products in all major markets including USA, UK, Europe, Canada, Australia & Russia. Of this, US alone is potentially a USD9 billion market
New approvals : 6 new approvals are awaited in US
Manufacturing capabilities with regulatory approvals : Marksans’ Goa facility has a capacity to turn out 2.4 billion softgel capsules per annum, and has all the necessary approvals by USFDA, UKMHRA, TGA & other key regulatory authorities

Forward Integrated Business Model

==> picture [865 x 389] intentionally omitted <==

----- Start of picture text -----

R&D and
Manufacturing
Goa & Mumbai (India) Southport (UK) Farmingdale (US)
Supply chain and EXPORT
distribution
Australasia UK/Europe UK & Europe North America / Canada ROW
End Consumers
Retail chains Pharmacy stores Hospitals
Mumbai has only R&D center in Navi Mumbai
----- End of picture text -----

==> picture [960 x 242] intentionally omitted <==

Research & development

R&D Continues to be the Backbone of the Marksans

In FY20, total R&D expenditure was Rs. 8.3 crore

R&D Expenditure (₹ Crores)

R&D activities comprises of:

==> picture [323 x 141] intentionally omitted <==

----- Start of picture text -----

14.6
8.3
5.3
4.5
2016-17 2017-18 2018-19 2019-20
----- End of picture text -----

Developing generic products and pharmaceutical formulations
Identifying niche areas (such as cardiovascular diseases, diabetes and neuroscience) for product development
Post-patent filing for regulated and emerging markets
Collaborating with partners in developing drugs going off-patent

KEY HIGHLIGHTS

Marksans newly commissioned state of art R&D center apart from the existing Goa facility, at Navi Mumbai fosters its foray into new segments, cater to hitherto unmet globally therapeutic needs and enhance the Company’s opportunity responsiveness and to file a larger number of ANDAs
Team of over 50 experienced scientists specializing in new drug delivery systems, formulation development and analytical development
The company continues to maintain regulatory certifications with MHRA, TGA and USFDA, based on recent inspections
Marksans’s ability to formulate and market a drug in the shortest possible lead time has given the business a critical competitive advantage

==> picture [960 x 242] intentionally omitted <==

Segmental revenue composition

Global Reach Enables Reduction in Country Risk

REVENUE MIX

Company’s business is classified under 4 heads:

North America/ US generics
Europe/UK generics
Australia and New Zealand
Rest of the world (RoW) generics (CIS, Middle Eastern, African and South-East Asian countries)

==> picture [530 x 281] intentionally omitted <==

----- Start of picture text -----

Europe, UK US, North America Australia, NZ RoW
6% 4% 3% 6% 4%
11%
12% 14% 12% 12%
36% 41% 39%
41%
45%
46% 45% 45%
41%
37%
FY16 FY17 FY18 FY19 FY20
----- End of picture text -----

==> picture [234 x 42] intentionally omitted <==

The UK is the highest contributor to Marksans Pharma’ s revenues

Overview of the market

The UK

510.0

Total revenues (र Cr.)

The UK pharmaceutical market is estimated to grow from ~USD 29 billion in 2015 to ~USD 43 billion by 2020, at a CAGR of 8.4%, driven primarily by a robust life sciences industry

Company presence

One of the top 5 Indian pharma companies in the UK
UK business is driven by its two subsidiaries, Relonchem and Bell
Bell has a strong OTC portfolio with 50+ products
Relonchem’s portfolio comprises high-end Rx portfolio of 100+ products

23.5[%]

Y-o-y growth

45.0[%]

Contribution to total revenues

Outlook

Company has 50+ products in the pipeline in different stages to carter UK market
Company is awaiting approval for ~20 MAs in the UK market

Marksans is among a few Indian players with a proprietary marketing presence in the US

Overview of the market

The United States

436.4

Total revenues (र Cr.)

The US holds over 30-40% of the global pharmaceutical market. It at a is expected to reach USD 190.4 billion by 2024,
projected CAGR of 10.6% during 2019-2024, due to favoring government programs and policies

Company presence

In June 2015, Marksans acquired Time-Cap Labs which enabled Marksans to expand its offering in US market
30+ products, positioned in the niche soft gel category
Proprietary marketing presence with 100% integration of TimeCap Laboratories
Strong distribution channel marketing for both OTC and Rx products

6.1[%]

Y-o-y growth

38.5[%]

Contribution to total revenues

Outlook

Strengthen company’s US operations in the coming years
• Add 4-5 new products to its portfolio during the year under review

Australia and NZ region continue to deliver high teens growth in FY20

Overview of the market

Australia and New Zealand

140.7 Total Revenues (र Cr.)

Australia’s pharmaceutical market is set to rise from >$22.85 billion in 2016 to $25.2 billion by 2020 registering a CAGR of 2%

Company presence

Marksans carries out business operations in Australia and New Zealand through its subsidiary Nova Pharmaceuticals
• Nova is one of the leading generics and private label suppliers in Australia
Tie-ups with topmost retailers & pharmacies in Australia, like Woolworths Ltd., Coles Mayer Ltd., Aldis, Metcash and Fauldings

17.3[%]

Y-o-y growth

12.4[%]

Contribution to total revenues

Presence in key therapeutic areas

Outlook

Australia and New Zealand will continue to remain focus markets for the Company

After harnessing the regulated markets, Marksans is venturing out in the emerging countries

Overview of the markets

ROW includes markets of South East Asia, MENA, Russian Federation & Africa

47.4

Rest of Total Revenues the world (र Cr.) -21.3[%] 4.2[%] Y-o-y growth Contribution to total revenues

Company presence

Targeting four major clusters such as South East Asia, Russia and the CIS, Middle East and Africa
In these four clusters, specific countries like Iraq, Kenya, Ukraine, Sri Lanka and Myanmar are targeted
Started filing for approvals in these countries

Outlook

Company is strengthening its presence in the target markets and expects to generate 10% of the Company’s revenue by FY22

==> picture [960 x 242] intentionally omitted <==

Investment Rationale

Investment Rationale

==> picture [78 x 78] intentionally omitted <==

==> picture [78 x 77] intentionally omitted <==

==> picture [78 x 78] intentionally omitted <==

Company is widening its products portfolio in the complex and high-margin generics segment

Marksans is among a handful of Indian players with a proprietary marketing presence in the US which is world’s largest pharma market

The new state-of-the-art R&D center in Navi Mumbai (Nerul) is focused on formulations and novel drug delivery systems

==> picture [78 x 78] intentionally omitted <==

==> picture [78 x 77] intentionally omitted <==

==> picture [78 x 78] intentionally omitted <==

The US, the UK and Australia are the key Marksans’ markets with all of them being now empowered with all regulatory approvals

Marksans is among a few mid and small-sized pharma companies to have created an integrated business model by engaging R&D team in creating and filing dossiers across major markets

Company has repaid longterm loans, deleveraged the Balance Sheet and reinvested the surplus in R&D, capacity creation and brownfield expansion

==> picture [234 x 42] intentionally omitted <==

==> picture [85 x 86] intentionally omitted <==

==> picture [381 x 34] intentionally omitted <==

Investor Relations Team at Marksans Pharma

Jitendra Sharma, CFO Marksans Pharma Ltd Tel: +91 022 40012000 [email protected]

Dikshita Jain Christensen Investor Relations Tel : +91 22 4215 0210 [email protected]

Corporate Office: 11th Floor Grandeur, Off Veera Desai Road, Opp Gundecha Symphony, Andheri (W), Mumbai 400 053. Maharashtra - India

“Marksans Pharma” and The Marksans Pharma Logo are trademarks of Marksans Pharma Limited. In addition to Company data, data from market research agencies, Stock Exchanges and industry publications has been used for this presentation. This material was used during an oral presentation; it is not a complete record of the discussion. This work may not be used, sold, transferred, adapted, abridged, copied or reproduced in whole on or in part in any manner or form or in any media without the prior written consent. All product names and company names and logos mentioned herein are the trademarks or registered trademarks of their respective owners.

AI assistant

Marksans Pharma Ltd. — Investor Presentation 2020

62142_rns_2020-06-02_6ccf2d51-f357-4322-ac1d-ad84beec6efc.pdf

Safe Harbor

FY20 Highlights

Operational Excellence leading to positive margin & return ratios

Agenda

Q4 & FY20 Performance Review

Growth in Profitability

Key Highlights

Financials

Business Review

Key Highlights

Almost 96% of company's total revenue came from regulated markets of US, Europe, Australia and New Zealand

Operational review and financials

Consolidated Revenue up 12.9% led by Strong Growth in Europe and Australia

Topline driven by key geographies

US Region:

UK Europe:

EBITDA Margin Increased by 336 bps during FY20 – Strong Growth Expected in FY 21

Steady growth in the profitability

Balance Sheet Trends (Mar 20 vs Mar 19)

Company at a glance

Company Overview

Business Description

Business Model

Marksans Pharma Evolution

Business Model

Wider product basket

Company Structure

Manufacturing Capabilities

Capacity

Capacity

Long-term strategy

Strategic focus on Regulated Markets

Marksans Pharma generates ~96% of its revenues from regulated markets

Niche Formulations with few Competitors

Marksans Pharma is currently one of the most active Indian firms focused in Softgel segment

Forward Integrated Business Model

Research & development

R&D Continues to be the Backbone of the Marksans

In FY20, total R&D expenditure was Rs. 8.3 crore

R&D Expenditure (₹ Crores)

R&D activities comprises of:

KEY HIGHLIGHTS

Segmental revenue composition

Global Reach Enables Reduction in Country Risk

REVENUE MIX

The UK is the highest contributor to Marksans Pharma’ s revenues

Overview of the market

Company presence

Outlook

Marksans is among a few Indian players with a proprietary marketing presence in the US

Overview of the market

Company presence

6.1[%]

38.5[%]

Outlook

Australia and NZ region continue to deliver high teens growth in FY20

Overview of the market

Company presence

Outlook

After harnessing the regulated markets, Marksans is venturing out in the emerging countries

Overview of the markets

Company presence

Outlook

Investment Rationale

© 2019 Marksans Pharma Limited, All Rights Reserved.

More from Marksans Pharma Ltd.

Marksans Pharma Ltd. Investor Presentation 2020